innovent glp-1 China's says its works better than Novo's semaglutide in diabetes study GLP-1-based therapies for diabetes, obesity

doi: 10.20960/nh.02746

A p-value less than 0.05 was considered significant

This title was summarized by AI from the post below

Our best outcomes are those where interventions are scaffolding, not crutches

Considering that OSAS patients often present with multiple comorbiditiessuch as hypertension, coronary artery disease, and diabetesfurther large-scale, long-term follow-up studies are needed to clarify tirzepatides safety in multimorbid populations (63, 64)

Practical factorssuch as insurance coverage, approved indication (type 2 diabetes vs obesity), drug availability, previous side effects, and co-existing health conditionsusually matter more than subtle mechanistic differences when deciding which medication to use and how aggressively to dose it